BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 21861257)

  • 1. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
    Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
    Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland].
    Jahnz-Rózyk K; Targowski T; From S
    Pneumonol Alergol Pol; 2008; 76(6):426-31. PubMed ID: 19173191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
    Jahnz-Rózyk K; Targowski T; From S
    Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
    Chiang CH
    Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations].
    Jahnz-Rózyk K; Targowski T; From S; Płusa T
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():91-4. PubMed ID: 15524028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
    Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS
    COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of chronic obstructive pulmonary disease.
    Teo WS; Tan WS; Chong WF; Abisheganaden J; Lew YJ; Lim TK; Heng BH
    Respirology; 2012 Jan; 17(1):120-6. PubMed ID: 21954985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Estimation of direct medical costs of chronic obstructive pulmonary disease over 12 months].
    Stâmbu I; Stoicescu IP
    Pneumologia; 2013; 62(2):86-92. PubMed ID: 23894789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care].
    Faber M; Jahnz-Rózyk K; Kucharczyk A; Targowski T; From S; Mamełka B
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():96-9. PubMed ID: 15524029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls.
    Bilde L; Rud Svenning A; Dollerup J; Baekke Borgeskov H; Lange P
    Respir Med; 2007 Mar; 101(3):539-46. PubMed ID: 16889949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct medical costs of COPD--an excess cost approach based on two population-based studies.
    Menn P; Heinrich J; Huber RM; Jörres RA; John J; Karrasch S; Peters A; Schulz H; Holle R;
    Respir Med; 2012 Apr; 106(4):540-8. PubMed ID: 22100535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between disease severity, smoking index age and direct costs of hospital treatment of COPD exacerbations].
    Targowski T; Jahnz-Rózyk K; From S; Płusa T
    Pneumonol Alergol Pol; 2005; 73(1):32-5. PubMed ID: 16539181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.
    Mittmann N; Kuramoto L; Seung SJ; Haddon JM; Bradley-Kennedy C; Fitzgerald JM
    Respir Med; 2008 Mar; 102(3):413-21. PubMed ID: 18086519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health economic impact of viral respiratory infections and pneumonia diseases on the elderly population in Poland].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2010 Jul; 29(169):37-40. PubMed ID: 20712246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of heart failure in Poland from the public payer's perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD.
    Czech M; Opolski G; Zdrojewski T; Dubiel JS; Wizner B; Bolisęga D; Fedyk-Łukasik M; Grodzicki T
    Kardiol Pol; 2013; 71(3):224-32. PubMed ID: 23575775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study.
    Lisspers K; Johansson G; Jansson C; Larsson K; Stratelis G; Hedegaard M; Ställberg B
    Respir Med; 2014 Sep; 108(9):1345-54. PubMed ID: 25002194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Introduction to asthma and chronic obstructive pulmonary disease pharmacoeconomics].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():5-6, 8. PubMed ID: 15524004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease.
    Dalal AA; Shah M; Lunacsek O; Hanania NA
    Respir Med; 2011 Oct; 105(10):1516-22. PubMed ID: 21684731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden.
    Tunsäter A; Moutakis M; Borg S; Persson U; Strömberg L; Nielsen AL
    Health Policy; 2007 May; 81(2-3):309-19. PubMed ID: 16904788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.